cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.22002/3m4bf-r7j59
title: Lp02_2nd

description: 2nd time collection: Jan 2016. Defocus -6.Lp02 is thymidine auxotroph of the parental strain Lp01 originating from Philadelphia-1 strain. Cells were grown in AYE liquid culture with following supplements: ferric nitrate, cysteine hydrochloride and thymidine. Scrape cells off a plate, dissolve in the media, adjust the cell density to 0.6 and make a dilution series. Start O/N culture with all of them and freeze cells next day from the one in early stationary phase that is OD ~ 3.0
description: <strong>Tilt Series Date:</strong> 2016-01-15</p>
<strong>Data Taken By:</strong> Debnath Ghosal</p>
<strong>Species / Specimen:</strong> Legionella pneumophila</p>
<strong>Strain:</strong> Philadelphia-1_Lp02</p>
<strong>Tilt Series Settings:</strong>  Single Axis, tilt range: (-60.0°, 60.0°), step: 1.50°, constant angular increment, dosage: 100.0 eV/Å²,  defocus: -6.0 μm,  magnification: 26000x. </p>
<strong>Microscope:</strong> Janelia Titan</p>
<strong>Acquisition Software:</strong> UCSFTomo</p>
<strong>Upload Method:</strong> pipeline</p>
<strong>Processing Software Used:</strong> Raptor</p>
<strong>Collaborators and Roles:</strong> Strain sent to us by Joseph P. Vogel, Washington University School of Medicine. Data collected and processed by Debnath Ghosal. This data was collected at the Janelia Krios.</p>
<strong>Purification / Growth Conditions / Treatment:</strong> Lp02 is thymidine auxotroph of the parental strain Lp01 originating from Philadelphia-1 strain. Cells were grown in AYE liquid culture with following supplements: ferric nitrate, cysteine hydrochloride and thymidine. Scrape cells off a plate, dissolve in the media, adjust the cell density to 0.6 and make a dilution series. Start O/N culture with all of them and freeze cells next day from the one in early stationary phase that is OD ~ 3.0. Added gold before freezing.</p>
<strong>Sample Preparation:</strong> Grids were stored in Janelia from previous imaging. See previous Lp02 sample prep. Vitrobot (MK iv) settings: 100% humidity, 4µl sample, Blot force 6, blot time 3 sec. Wait time 0 sec. Drain time 1 sec. Ethane/propane mix. Grid: Quantifoil Cu 2/2 200. Add gold to cells prior to freezing: 1ul of gold to 4 ul of cells, freeze.</p>
  dga2016-01-15-44_slicer16661.jpg: Interesting membrane vesicle!
description: Files available via S3 at https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2016-01-15-44/rawdata/</p>tomo_area1000100010024.mrc,  Tilt Series (Pixel Size 0.42 nm), 2.2 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2016-01-15-44/rawdata/tomo_area1000100010024.mrc"
        > <i class="download icon"></i> Download </a></p>

        tomo_area1000100010024_full.rec,  Reconstruction (Pixel Size 1.68 nm), 430.6 MB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2016-01-15-44/3dimage_72871/tomo_area1000100010024_full.rec"
        > <i class="download icon"></i> Download </a></p>
DOI: 10.22002/1k0bp-w8435
title: Lp02_Legionella pneumophila

description: Lp02 is thymidine auxotroph of the parental strain Lp01 originating from Philadelphia-1 strain. Cells were grown in  AYE liquid culture with following supplements: ferric nitrate, cysteine hydrochloride and thymidine. Scrape cells off a plate, dissolve in the media, adjust the cell density to 0.6 and make a dilution series. Start O/N culture with all of them and freeze cells next day from the one in early stationary phase that is OD ~ 3.0
description: <strong>Tilt Series Date:</strong> 2015-10-29</p>
<strong>Data Taken By:</strong> Debnath Ghosal</p>
<strong>Species / Specimen:</strong> Legionella pneumophila</p>
<strong>Strain:</strong> Philadelphia-1_Lp02</p>
<strong>Tilt Series Settings:</strong>  Single Axis, tilt range: (-60.0°, 60.0°), step: 1.0°, constant angular increment, dosage: 100.0 eV/Å²,  defocus: -8.0 μm,  magnification: 26000x. </p>
<strong>Microscope:</strong> Janelia Titan</p>
<strong>Acquisition Software:</strong> UCSFTomo</p>
<strong>Upload Method:</strong> pipeline</p>
<strong>Processing Software Used:</strong> Raptor, also manually processed 25 tomograms (and used SIRT)for subtomogram averaging.</p>
<strong>Collaborators and Roles:</strong> Strain sent to us by Joseph P. Vogel, Washington University School of Medicine. Data collected and processed by Debnath Ghosal. This data was collected at the Janelia Krios.</p>
<strong>Purification / Growth Conditions / Treatment:</strong> Lp02 is thymidine auxotroph of the parental strain Lp01 originating from Philadelphia-1 strain. Cells were grown in  AYE liquid culture with following supplements: ferric nitrate, cysteine hydrochloride and thymidine. Scrape cells off a plate, dissolve in the media, adjust the cell density to 0.6 and make a dilution series. Start O/N culture with all of them and freeze cells next day from the one in early stationary phase that is OD ~ 3.0. Added gold before freezing.</p>
<strong>Sample Preparation:</strong> 4 grids were frozen for Lp02 at OD= 2.8 and another 4 grids for Lp02 at OD= 3.3Vitrobot (MK iv) settings: 100% humidity, 4µl sample, Blot force 6, blot time 3 sec. Wait time 0 sec. Drain time 1 sec. Ethane/propane mix. Grid: Quantifoil Cu 2/2 200.Add gold to cells prior to freezing: 1ul of gold to 4 ul of cells, freeze.</p>
description: Files available via S3 at https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2015-10-29-63/3dimage_70761/</p>20151029_LP02_10063_part121_2.rec,  Reconstruction (Pixel Size 1.68 nm), 430.6 MB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2015-10-29-63/3dimage_70761/20151029_LP02_10063_part121_2.rec"
        > <i class="download icon"></i> Download </a></p>

        20151029_LP02_10063.mrc,  Tilt Series (Pixel Size 0.42 nm), 3.3 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2015-10-29-63/rawdata/20151029_LP02_10063.mrc"
        > <i class="download icon"></i> Download </a></p>
DOI: 10.22002/840dp-gg963
title: Lp02_Legionella pneumophila

description: Lp02 is thymidine auxotroph of the parental strain Lp01 originating from Philadelphia-1 strain. Cells were grown in  AYE liquid culture with following supplements: ferric nitrate, cysteine hydrochloride and thymidine. Scrape cells off a plate, dissolve in the media, adjust the cell density to 0.6 and make a dilution series. Start O/N culture with all of them and freeze cells next day from the one in early stationary phase that is OD ~ 3.0
description: <strong>Tilt Series Date:</strong> 2015-10-29</p>
<strong>Data Taken By:</strong> Debnath Ghosal</p>
<strong>Species / Specimen:</strong> Legionella pneumophila</p>
<strong>Strain:</strong> Philadelphia-1_Lp02</p>
<strong>Tilt Series Settings:</strong>  Single Axis, tilt range: (-60.0°, 60.0°), step: 1.0°, constant angular increment, dosage: 100.0 eV/Å²,  defocus: -8.0 μm,  magnification: 26000x. </p>
<strong>Microscope:</strong> Janelia Titan</p>
<strong>Acquisition Software:</strong> UCSFTomo</p>
<strong>Upload Method:</strong> pipeline</p>
<strong>Processing Software Used:</strong> Raptor, also manually processed 25 tomograms (and used SIRT)for subtomogram averaging.</p>
<strong>Collaborators and Roles:</strong> Strain sent to us by Joseph P. Vogel, Washington University School of Medicine. Data collected and processed by Debnath Ghosal. This data was collected at the Janelia Krios.</p>
<strong>Purification / Growth Conditions / Treatment:</strong> Lp02 is thymidine auxotroph of the parental strain Lp01 originating from Philadelphia-1 strain. Cells were grown in  AYE liquid culture with following supplements: ferric nitrate, cysteine hydrochloride and thymidine. Scrape cells off a plate, dissolve in the media, adjust the cell density to 0.6 and make a dilution series. Start O/N culture with all of them and freeze cells next day from the one in early stationary phase that is OD ~ 3.0. Added gold before freezing.</p>
<strong>Sample Preparation:</strong> 4 grids were frozen for Lp02 at OD= 2.8 and another 4 grids for Lp02 at OD= 3.3Vitrobot (MK iv) settings: 100% humidity, 4µl sample, Blot force 6, blot time 3 sec. Wait time 0 sec. Drain time 1 sec. Ethane/propane mix. Grid: Quantifoil Cu 2/2 200.Add gold to cells prior to freezing: 1ul of gold to 4 ul of cells, freeze.</p>
description: Files available via S3 at https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2015-10-29-68/3dimage_70773/</p>20151029_LP02_10068_full.rec,  Reconstruction (Pixel Size 1.68 nm), 430.6 MB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2015-10-29-68/3dimage_70773/20151029_LP02_10068_full.rec"
        > <i class="download icon"></i> Download </a></p>

        20151029_LP02_10068.mrc,  Tilt Series (Pixel Size 0.42 nm), 3.3 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2015-10-29-68/rawdata/20151029_LP02_10068.mrc"
        > <i class="download icon"></i> Download </a></p>
DOI: 10.6084/m9.figshare.30009052
title: Supplementary Material for: Early-Onset Stargardt Disease Caused by Homozygosity of a Complex ABCA4 Allele from Eastern Africa: Two Case Reports

description: Introduction:
Biallelic pathogenic variants in the ABCA4 gene are the leading cause of inherited retinal diseases (IRDs). Over 1,200 pathogenic or likely pathogenic ABCA4 variants have been reported, resulting in a broad clinical spectrum of ABCA4-retinal dystrophies (ABCA4-RD), with Stargardt disease being the most common. Most patients with ABCA4-RD are compound heterozygotes, carrying two pathogenic ABCA4 variants in trans.
Case Presentation:
We report two unrelated patients with early-onset (≤12 years) Stargardt disease, both found to be homozygous for a complex ABCA4 allele containing the hypomorphic c.5882G&gt;A p.(Gly1961Glu) variant and the c.634C&gt;T p.(Arg212Cys) variant. Both patients underwent detailed clinical assessment and genetic screening, including whole exome or genome sequencing. In vitro assays were performed to assess the individual and combined effect of these variants on the ABCA4 protein. The identified ABCA4 variants were expressed in HEK293FT and HeLa cells to assess their protein expression levels and intracellular localization compared to the wild type (WT) ABCA4 protein. Molecular analysis revealed that the Arg212Cys variant and the doubly mutated allele showed similarly reduced protein expression, while Gly1961Glu expressed close to WT level. Both variants, individually and combined, localized to intracellular vesicles similarly to WT ABCA4. 
Conclusion:
This study highlights the genetic complexity of ABCA4-RD and the significance of pathogenic variants in cis. It also emphasizes the challenge of accurately predicting the functional consequences of specific ABCA4 alleles with in vitro assays.
DOI: 10.6084/m9.figshare.30009052.v1
title: Supplementary Material for: Early-Onset Stargardt Disease Caused by Homozygosity of a Complex ABCA4 Allele from Eastern Africa: Two Case Reports

description: Introduction:
Biallelic pathogenic variants in the ABCA4 gene are the leading cause of inherited retinal diseases (IRDs). Over 1,200 pathogenic or likely pathogenic ABCA4 variants have been reported, resulting in a broad clinical spectrum of ABCA4-retinal dystrophies (ABCA4-RD), with Stargardt disease being the most common. Most patients with ABCA4-RD are compound heterozygotes, carrying two pathogenic ABCA4 variants in trans.
Case Presentation:
We report two unrelated patients with early-onset (≤12 years) Stargardt disease, both found to be homozygous for a complex ABCA4 allele containing the hypomorphic c.5882G&gt;A p.(Gly1961Glu) variant and the c.634C&gt;T p.(Arg212Cys) variant. Both patients underwent detailed clinical assessment and genetic screening, including whole exome or genome sequencing. In vitro assays were performed to assess the individual and combined effect of these variants on the ABCA4 protein. The identified ABCA4 variants were expressed in HEK293FT and HeLa cells to assess their protein expression levels and intracellular localization compared to the wild type (WT) ABCA4 protein. Molecular analysis revealed that the Arg212Cys variant and the doubly mutated allele showed similarly reduced protein expression, while Gly1961Glu expressed close to WT level. Both variants, individually and combined, localized to intracellular vesicles similarly to WT ABCA4. 
Conclusion:
This study highlights the genetic complexity of ABCA4-RD and the significance of pathogenic variants in cis. It also emphasizes the challenge of accurately predicting the functional consequences of specific ABCA4 alleles with in vitro assays.
DOI: 10.22002/6v1b4-8m833
title: JV7091_ΔdotEP

description: JV7091_ΔdotEP (Deletion of dotE and dotP)
description: <strong>Tilt Series Date:</strong> 2017-10-31</p>
<strong>Data Taken By:</strong> Debnath Ghosal</p>
<strong>Species / Specimen:</strong> Legionella pneumophila</p>
<strong>Strain:</strong> Philadelphia-1_Lp02</p>
<strong>Tilt Series Settings:</strong>  Single Axis, tilt range: (-60.0°, 60.0°), step: 2°, constant angular increment, dosage: 100.0 eV/Å²,  defocus: -7.0 μm,  magnification: 27500x. </p>
<strong>Microscope:</strong> Caltech Polara</p>
<strong>Acquisition Software:</strong> UCSFTomo</p>
<strong>Upload Method:</strong> pipeline</p>
<strong>Processing Software Used:</strong> Raptor</p>
<strong>Collaborators and Roles:</strong> Strain sent to us by Joseph P. Vogel, Washington University School of Medicine. Data collected and processed by Debnath Ghosal at F30, Caltech.</p>
<strong>Purification / Growth Conditions / Treatment:</strong> Cells were grown in AYE liquid culture with following supplements: ferric nitrate, cysteine hydrochloride and thymidine. Scrape cells off a plate, dissolve in the media, adjust the cell density to 0.6 and make a dilution series. Start O/N culture with all of them and freeze cells next day from the one in early stationary phase that is OD ~ 3.0. This time cell density was ~2.8</p>
<strong>Sample Preparation:</strong> 6 grids were frozen for this strain at OD~ 2.8, cell density was increased to 2x by centrifugation. Vitrobot (MK iv) settings: 100% humidity, 4µl sample, Blot force 6, blot time 4 sec. Wait time 0 sec. Drain time 1 sec. Ethane/propane mix. Grid: Quantifoil Cu 2/2 200. Add gold to cells prior to freezing: 1ul of gold to 4 ul of cells, freeze.</p>
description: Files available via S3 at https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2017-10-31-51/rawdata/</p>JV7091-20171030a0053.mrc,  Tilt Series (Pixel Size 0.39 nm), 1.7 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2017-10-31-51/rawdata/JV7091-20171030a0053.mrc"
        > <i class="download icon"></i> Download </a></p>

        JV7091-20171030a0053_part61_3.rec,  Reconstruction (Pixel Size 1.56 nm), 445.4 MB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2017-10-31-51/3dimage_89983/JV7091-20171030a0053_part61_3.rec"
        > <i class="download icon"></i> Download </a></p>
DOI: 10.6084/m9.figshare.30009055
title: Supplementary Material for: Commonality analysis of high-quality acupuncture clinical trial articles

description: Background: With a wide range of clinical needs, evidence-based support for acupuncture therapy through clinical trials is essential for enhancing its scientific value, clinical application, and international influence.
Objective: To provide design ideas and specific methodology references for acupuncturists and researchers for the design, implementation, and publication of high-level acupuncture clinical research.
Data sources: The data came from Pubmed, Web of Science, and EBSCO databases since its inception until February 28, 2024. A total of 91 articles were retrieved, and the primary interventions were manual acupuncture, electroacupuncture, auricular acupuncture, and laser acupuncture. 85 clinical trials on manual acupuncture and electroacupuncture as primary interventions were included.
Results: All of the high-quality clinical trial publications on acupuncture included in the review adhered to the Consolidated Standards of Reporting Trials (CONSORT) statement and the Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA). They demonstrated rigor and accuracy in trial design selection, inclusion criteria development, sample size calculations, statistical methodology, and provided clear, concise details of acupuncture interventions and control settings.
Conclusion: These trials have elevated the overall quality of the research and provided invaluable insights and methodological frameworks for designing randomized controlled trials (RCTs) in acupuncture. Despite these advancements, several limitations remain that warrant attention in future endeavors. Addressing these shortcomings is crucial for enhancing the methodological rigor and reliability of acupuncture trials and advancing evidence-based practice in this field.
DOI: 10.6084/m9.figshare.30009055.v1
title: Supplementary Material for: Commonality analysis of high-quality acupuncture clinical trial articles

description: Background: With a wide range of clinical needs, evidence-based support for acupuncture therapy through clinical trials is essential for enhancing its scientific value, clinical application, and international influence.
Objective: To provide design ideas and specific methodology references for acupuncturists and researchers for the design, implementation, and publication of high-level acupuncture clinical research.
Data sources: The data came from Pubmed, Web of Science, and EBSCO databases since its inception until February 28, 2024. A total of 91 articles were retrieved, and the primary interventions were manual acupuncture, electroacupuncture, auricular acupuncture, and laser acupuncture. 85 clinical trials on manual acupuncture and electroacupuncture as primary interventions were included.
Results: All of the high-quality clinical trial publications on acupuncture included in the review adhered to the Consolidated Standards of Reporting Trials (CONSORT) statement and the Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA). They demonstrated rigor and accuracy in trial design selection, inclusion criteria development, sample size calculations, statistical methodology, and provided clear, concise details of acupuncture interventions and control settings.
Conclusion: These trials have elevated the overall quality of the research and provided invaluable insights and methodological frameworks for designing randomized controlled trials (RCTs) in acupuncture. Despite these advancements, several limitations remain that warrant attention in future endeavors. Addressing these shortcomings is crucial for enhancing the methodological rigor and reliability of acupuncture trials and advancing evidence-based practice in this field.
DOI: 10.22002/99ncj-1td17
title: JV3559_Janelia

description: Legionella thyA ΔdotG.This is a single mutant that lacks DotG.
description: <strong>Tilt Series Date:</strong> 2017-01-08</p>
<strong>Data Taken By:</strong> Debnath Ghosal</p>
<strong>Species / Specimen:</strong> Legionella pneumophila</p>
<strong>Strain:</strong> Philadelphia-1_Lp02</p>
<strong>Tilt Series Settings:</strong>  Single Axis, tilt range: (-60.0°, 60.0°), step: 1.50°, constant angular increment, dosage: 100.0 eV/Å²,  defocus: -6.0 μm,  magnification: 26000x. </p>
<strong>Microscope:</strong> Janelia Titan</p>
<strong>Acquisition Software:</strong> UCSFTomo</p>
<strong>Upload Method:</strong> pipeline</p>
<strong>Processing Software Used:</strong> Raptor</p>
<strong>Collaborators and Roles:</strong> Strain sent to us by Joseph P. Vogel, Washington University School of Medicine. Data collected and processed by Debnath Ghosal at F30, Caltech.</p>
<strong>Purification / Growth Conditions / Treatment:</strong> Cells were grown in AYE liquid culture with following supplements: ferric nitrate, cysteine hydrochloride and thymidine. Scrape cells off a plate, dissolve in the media, adjust the cell density to 0.6 and make a dilution series. Start O/N culture with all of them and freeze cells next day from the one in early stationary phase that is OD ~ 3.0. This time cell density was ~3.4</p>
<strong>Sample Preparation:</strong> 8 grids were frozen for the JV3559 strain at OD~ 3.4, 4 grids at density x and another 4 at density 2x. Vitrobot (MK iv) settings: 100% humidity, 4µl sample, Blot force 6, blot time 3 sec. Wait time 0 sec. Drain time 1 sec. Ethane/propane mix. Grid: Quantifoil Cu 2/2 200. Add gold to cells prior to freezing: 1ul of gold to 4 ul of cells, freeze.</p>
description: Files available via S3 at https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2017-01-08-107/3dimage_80439/</p>JV3559_20170108a_area20011_full.rec,  Reconstruction (Pixel Size 1.68 nm), 445.4 MB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2017-01-08-107/3dimage_80439/JV3559_20170108a_area20011_full.rec"
        > <i class="download icon"></i> Download </a></p>

        JV3559_20170108a_area20011.mrc,  Tilt Series (Pixel Size 0.42 nm), 2.3 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2017-01-08-107/rawdata/JV3559_20170108a_area20011.mrc"
        > <i class="download icon"></i> Download </a></p>
DOI: 10.6084/m9.figshare.30009058
title: Supplementary Material for: Trends and Impact of Early Medical Complications in Acute Ischemic Stroke: Data from the Austrian Stroke Unit Registry

description: Introduction
Early medical complications following acute ischemic stroke (AIS) are common and might increase post-stroke morbidity and mortality. This study aimed to evaluate trends in the prevalence of early medical complications over almost two decades and their impact on three-month functional outcome and mortality.

Methods
A total of 181,704 AIS patients from the Austrian Stroke Unit Registry (2006-2024) were analyzed. Early medical complications included decompensated heart failure, cardiac arrythmia, sepsis, pneumonia, urinary tract infection (UTI), deep vein thrombosis, and pulmonary embolism. Functional outcomes were assessed using the modified Rankin Scale (mRS) after three-months, with favorable outcome defined as mRS ≤1. Associations between early medical complications and mRS were analyzed using multivariable Poisson regression models.

Results
Among all patients, 16,279 (9.0%) had early medical complications. Pneumonia (4.2%), UTI (2.9%), cardiac arrhythmia (1.4%), and decompensated heart failure (1.4%) were most common, with significant declines in prevalences over time. Admission NIHSS scores decreased, and the use of intravenous thrombolysis and mechanical thrombectomy increased. Decompensated heart failure (RR = 1.85, 95% CI 1.73-1.97, p &lt;0.001), sepsis (RR = 1.75, 95% CI 1.53-1.99, p &lt;0.001), pulmonary embolism (RR = 1.67, 95% CI 1.33-2.10, p &lt;0.001), and pneumonia (RR = 1.64, 95% CI 1.57-1.72, p &lt;0.001) were significantly associated with three-month mortality. Furthermore, the complications least associated with a favorable outcome were pneumonia (RR = 0.36, 95% CI 0.32-0.41, p &lt;0.001), decompensated heart failure (RR = 0.38, 95% CI 0.32-0.46, p &lt;0.001), and sepsis (RR = 0.59, 95% CI 0.45-0.77, p &lt;0.001). The effect sizes didn’t change significantly through the observed years.

Conclusions
This study observed a significant reduction in the prevalence of early medical complications after acute ischemic stroke. Especially decompensated heart failure, pneumonia, sepsis, and pulmonary embolism continue to substantially affect mortality and functional outcome in AIS patients.